Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Prochains essais cliniques
-
Seoul National University HospitalSamil Pharmaceutical Co., Ltd.RecrutementSarcopénie | Arthroplastie totale du genouCorée du Sud
-
Stanford UniversityPas encore de recrutementLeucémie myéloïde aiguë | Syndromes myélodysplasiques | Tumeur myéloproliférativeÉtats-Unis
-
Cheng QiRecrutementPost-hepatectomy HypoalbuminemiaChine
-
Stanford UniversityPas encore de recrutementInsuffisance hépatiqueÉtats-Unis
-
Istanbul Aydın UniversityPas encore de recrutementLa douleur du cou | Syndrome de douleur myofasciale | Troubles musculosquelettiques liés au travailTurquie (Türkiye)
-
Jonsson Comprehensive Cancer CenterStemline Therapeutics, Inc.Pas encore de recrutementCarcinome endométrial récurrent | Carcinome de l'endomètre avancé | Carcinome de l'endomètre métastatique | Cancer de l'endomètre de stade III | Cancer de l'endomètre de stade IVÉtats-Unis
-
University of Colorado, DenverRecrutementScoliose idiopathique de l'adolescent (AIS) | Scoliose neuromusculaireÉtats-Unis
-
University of FloridaAmerican Heart AssociationRecrutementInsuffisance cardiaque avec fraction d'éjection préservée (HFPEF)États-Unis
-
UNC Lineberger Comprehensive Cancer CenterPas encore de recrutementLeucémie | Leucémie aiguë lymphoblastique | Lymphome lymphoblastique | Leucémie aiguë | Leucémie lymphoïde aiguëÉtats-Unis
-
Korea University Anam HospitalThe Catholic University of Korea; Keimyung University Dongsan Medical Center; Medical AI Co., LtdPas encore de recrutementCancer urologique | Lésion myocardique après une chirurgie non cardiaque | Événements cardiovasculaires indésirables majeurs (masse)
-
Montefiore Medical CenterPas encore de recrutementCesarean Scar Defect (Isthmocele)États-Unis
-
SanofiPas encore de recrutementImmunisation contre le VRSTchéquie
Clinical Research Jobs
-
Philippines - Manila
-
Taiwan - Taipei
-
United States - Shrewsbury
-
Germany - Munich
-
Germany - Nordrhein-Westfalen - CologneAustria
-
Serbia - Belgrade
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China